Elective Dental Spending Is Up. Your Cases May Not Be.

Is elective dental spending actually falling in 2026?

No. Consumer dental spending was up 4% as of January 2026 compared with the twelve months prior, according to the ADA Health Policy Institute. What changed is not the total, it is the distribution. About one third of dentists now report they are not busy enough, per the same institute's Q1 2026 State of the U.S. Dental Economy reporting, which means the dollars are concentrating into fewer, larger, later decisions.

Both numbers come from the same body of research. They are not in conflict. They describe a market where the money is still there and the average chair is quieter, and the reconciliation of those two facts is the most useful thing a practice owner can understand right now.

Why can spending rise while a practice feels slow?

Aggregate dental spending is a big bucket. It holds hygiene, restorative work, emergency treatment, and everything insurance covers on a schedule. Most of that volume is not discretionary. A cracked molar does not wait for consumer confidence to recover.

The elective case is the swing line. Veneers, full-arch work, and comprehensive cosmetic treatment are the categories a patient can defer indefinitely without pain forcing the issue. When the ADA's Q1 2026 reporting notes that wait times are declining and patients are hesitating to undergo treatment, that hesitation lands disproportionately on the elective side of the schedule.

So the total can climb while your operatory feels slower, because the composition shifted underneath the total. One deferred full-arch case moves your month more than a dozen extra hygiene visits, and it is exactly the line item most exposed to a cautious consumer.

Here is the part worth sitting with. A soft consumer environment does not reduce what a patient wants. It lengthens the gap between wanting it and paying for it. The desire survives the economy. The timeline does not.

What does a hesitant patient actually cost the practice?

Most practices track case acceptance as a percentage, which is a reasonable number that hides a specific problem in a market like this one. A low-volume, high-value mix can sit inside a flat acceptance rate and disguise a real revenue decline. If you accepted eight of ten cases last year and eight of ten this year, but three of the ten you are no longer seeing were the big ones, your percentage is stable and your production is not.

Revenue per consult is the more honest instrument. It captures both whether the case closed and what the case was worth, and it moves when the mix shifts.

Then there is the compounding cost, which almost nobody prices. A case that leaves the operatory undecided does not get re-sold under the same conditions. It gets re-sold at a distance, over the phone or by email, against a memory that has gone cold, without the clinical context and without whatever the patient saw while they were sitting in your chair. The second attempt is structurally weaker than the first, and every extra day in that gap is a day the patient is deciding without the picture in front of them.

Reimbursement pressure makes the math tighter still. Dentists in the Q1 2026 reporting named low reimbursement rates and rising costs as their top concerns, which means the insurance-covered side of the practice is absorbing margin at the same time the elective side is stalling. The elective case is where the margin actually lives, and it is the one being deferred.

What should a practice do when patients are deferring elective care?

Let us name the wrong instincts first, because they are the popular ones.

Cutting the fee. This assumes the patient's objection is price. Often the objection is uncertainty about the result, and discounting an outcome the patient cannot picture does not resolve uncertainty. It just makes the same unresolved decision cheaper, and it permanently reprices your best-margin work.

Buying more new-patient traffic. If a third of dentists report they are not busy enough, more consults into the same funnel produces more undecided consults. You are paying acquisition cost to widen the top of a funnel that is leaking in the middle.

Adding a follow-up sequence after the visit. This is the most reasonable of the three and still fights the current. A deferring market is already lengthening the interval between interest and commitment. Building a process that lives entirely inside that interval accepts the premise that the decision happens later, somewhere you are not.

The lever that survives a soft market is different in kind. It shortens the distance between seeing the outcome and deciding on it. If hesitation is fundamentally a gap problem, then the answer is to compress the gap rather than to manage it more attentively.

This is why same-visit visualization behaves differently from the other three responses. Smile PreVue produces a photorealistic simulation in about 30 seconds, chairside on an iPad, with no additional hardware. The patient is not asked to imagine the result and report back. They decide while looking at their own face, in the room, with the clinician present to answer what comes up. It is HIPAA compliant and covered by a BAA on Vertex AI, which matters when the asset in question is a patient photograph.

The mechanism is not that a picture is persuasive. It is that a decision made with the evidence present is a different decision from one made three weeks later from memory.

How does this compare to the usual response?

Response	What it assumes about the patient	What it costs	What it does to margin
Discount the fee	The objection is price	Immediate revenue on every accepted case, plus a reset expectation for future work	Directly reduces it, permanently
More new-patient marketing	The problem is volume at the top	Rising acquisition cost per consult	Neutral at best, negative if consults still stall
Follow-up sequence after the visit	The decision happens later, elsewhere	Staff time on every unaccepted plan, at low conversion	Preserves fee, low yield
Same-visit visual decision	The objection is uncertainty about the result	Software cost, minutes of chair time	Preserves fee and closes the high-value case

The comparison worth drawing on the clinical side is Digital Smile Design. DSD is a serious planning protocol and it does real work, but it is structurally a multi-appointment process. The design is developed and the patient returns to see it. In a normal market that interval is an acceptable cost of thoroughness. In a market where patients are already stretching the interval before they commit, adding an appointment to the decision path adds risk to exactly the step that is failing.

That is the distinction. DSD is planning that happens between visits. Same-visit simulation is a decision that happens inside one.

Frequently asked questions

Is dental spending up or down in 2026? Up. Consumer dental spending was 4% higher as of January 2026 than in the prior twelve months, per the ADA Health Policy Institute. For context on the full-year picture, national dental care expenditures reached $189 billion in 2024, up 3.6% from 2023 after adjusting for inflation. That 2024 number is the latest available full-year figure and is reported on a lag, so it is not a current-year reading.

Why do practices feel slower if spending is up? Because the total is carried by non-discretionary care while elective cases stretch out. About a third of dentists report they are not busy enough even as the aggregate rises, which is what a distribution shift looks like from inside a single practice.

Do patients defer cosmetic work more than restorative work? Generally yes. Restorative and emergency care is driven by symptoms and has its own timeline. Cosmetic treatment is elective by definition, so it absorbs most of the hesitation when consumers get cautious.

Does financing fix elective deferral on its own? It removes one specific obstacle, the size of the payment, and that is genuinely useful. Smile PreVue lets a practice offer pay-in-full or pay-over-time options through Stripe, with pay-over-time provided by third parties such as Affirm, Klarna, or Sunbit and always subject to their approval. But financing answers "I cannot afford it right now." It does not answer "I am not sure I will like it," and in a hesitant market that second objection is the one doing the damage.

Is Smile PreVue HIPAA compliant? Yes. It is HIPAA compliant and BAA covered on Vertex AI, runs on an iPad with no additional hardware, and produces a simulation in about 30 seconds. There is a 3-day free trial through the App Store.

The short version

The market is not taking money out of dentistry. It is putting more time between the patient wanting the case and the patient paying for it. Every response that manages that interval instead of closing it concedes the point.

If you want to see what a same-visit decision looks like in your own operatory, start the 3-day free trial and run it on your next cosmetic consult.